Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 23andMe, Inc.
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
November 20, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
November 12, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
November 11, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
November 07, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Report Q2 FY2025 Financial Results
November 07, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Regains Compliance With Nasdaq Listing Requirements
October 30, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Appoints Three New Independent Directors to Board
October 29, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ANSS
CDLX
LSCC
ME
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
October 17, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Completion of 1-for-20 Reverse Stock Split
October 16, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces 1-for-20 Reverse Stock Split
October 11, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Mathew Knowles as New Brand Ambassador
October 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
September 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Independent Directors of 23andMe Resign from Board
September 17, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Tickers
ME
PTPI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
